Equal-WT
WhaleScore 2.0
?
Affinity Asset Advisors is based out of New York. Affinity Asset Advisors is a hedge fund with 2 clients and discretionary assets under management (AUM) of $553,053,373 (Form ADV from 2024-03-28). Their last reported 13F filing for Q2 2024 included $867,505,798 in managed 13F securities
and a top 10 holdings concentration of 48.78%. Affinity Asset Advisors's largest holding is SPDR S&P 500 ETF TRUST with shares held of 350,000. Whalewisdom has at least 16 13F filings, and 11 13G filings
Business Description
Affinity Asset Advisors, LLC, a Delaware limited liability company formed in 2017, is an investment advisor to private fund clients. The firm was founded by Michael Cho and Jonathan Chu, with Mr. Cho serving as the Portfolio Manager and Mr. Chu as the Chief Compliance Officer. Affinity's principal place of business is in New York, New York.
Affinity provides investment advisory services on a discretionary basis to private fund clients, including the Affinity Healthcare Fund, LP. The firm relies heavily on the services of its Portfolio Manager for all investment decisions, and investors have no right to participate in these decisions. As a result, the success of the clients depends largely on the abilities of key personnel, and any termination, death, or incapacitation of these individuals could negatively impact the profitability of the clients.
Investment Strategy
The Funds, through their investments in the Master Fund, pursue an active long-short equity strategy focused on the healthcare sector. Generally, healthcare investments will focus on pharmaceutical and biotechnology companies that develop, discover, and commercialize drug therapies.
The Funds, through the Master Fund, also invest opportunistically across the capital structure, including investments in credit instruments, private transactions, and alternative investments, which may include but are not limited to special purpose acquisition companies.
Owners
(Subscription Required)
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-06-30
Top Buys (13F)
| Name | % Change |
|---|---|
| SPY SPDR S&P 500 ETF TRU (PUT) | 21.96% |
| ALKS Alkermes Plc. | 1.55% |
| CLYM Climb Bio Inc. | 1.37% |
| CERE Cerevel Therapeutics (CALL) | 1.18% |
| INSM Insmed Inc | 0.97% |
2024-06-30
Top Sells (13F)
| Name | % Change |
|---|---|
| XBI SPDR(R) S&P(R) Biote (PUT) | 8.22% |
| MRNA Moderna Inc (PUT) | 5.28% |
| APLS Apellis Pharmaceutic | 1.2% |
| IRWD Ironwood Pharmaceuti (CALL) | 1.11% |
| BBIO BridgeBio Pharma Inc (CALL) | 0.96% |
2024-06-30
13F Holdings Summary
| Name | $ Change |
|---|---|
| SPY SPDR S&P 500 ETF TRU(PUT) | 21.96% |
| XENE Xenon Pharmaceutical | 4.47% |
| APGE Apogee Therapeutics | 3.79% |
| MDGL Madrigal Pharmaceuti | 3.55% |
| ACLX Arcellx Inc | 2.93% |
2024-06-30
13F Activity
| Market Value | $0.87b, Prior: $0.81b |
| Inflows (Outflows) as % of Total MV | +12.6352% |
| New Purchases | 32 stocks |
| Added To | 34 stocks |
| Sold out of | 29 stocks |
| Reduced holdings in | 20 stocks |
| Top 10 Holdings % | 48.78% |
| Turnover %[1] | 48.03% |
| Turnover Alt %[2] | 29.23% |
| Time Held Top 20 | 2.55 quarters |
| Time Held Top 10 | 1.6 quarters |
| Time Held All | 2.99 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-06-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-06-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-06-30